Human medicines European public assessment report (EPAR): Karvea, irbesartan, Date of authorisation: 26/08/1997, Revision: 48, Status: Authorised

Human medicines European public assessment report (EPAR): Karvea, irbesartan, Date of authorisation: 26/08/1997, Revision: 48, Status: Authorised

Opinion/decision on a Paediatric investigation plan (PIP): Skyrizi, Risankizumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Immunology-Rheumatology-Transplantation, PIP number: P/0492/2023

Opinion/decision on a Paediatric investigation plan (PIP): Skyrizi, Risankizumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Immunology-Rheumatology-Transplantation, PIP number: P/0492/2023

Union list of critical medicines: eXtended EudraVigilance Medicinal Product Dictionary (XEVMPD) / Product Management System (PMS) entries (outdated)

Union list of critical medicines: eXtended EudraVigilance Medicinal Product Dictionary (XEVMPD) / Product Management System (PMS) entries (outdated)

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.